Medical Marijuana | Parkinson’s Foundation

With medical marijuana now legalized in 38 states and the District of Columbia, there is strong interest in its therapeutic properties. Researchers are testing marijuana, which is also called cannabis, as a treatment for many illnesses and diseases, including Parkinson's disease (PD). However, despite this interest, there isnt conclusive scientific evidence that marijuana is beneficial in PD.

What is the science and pharmacology behind marijuana, and can it be used to treat Parkinson's symptoms?

The endocannabinoid system is located in the brain and made up of the endocannabinoids (molecules in our body that act on the cannabinoid receptors) and cannabinoid receptors (a molecular switch on the outside of a cell that makes something happen inside a cell when activated) on neurons (brain cells). The endocannabinoid system helps regulate many functions, including memory, pleasure, concentration, movement, appetite, and pain.

Researchers began to show enthusiasm to study cannabis in relation to PD after people with PD gave anecdotal reports and posted on social media as to how cannabis allegedly reduced their tremors. Some researchers think that cannabis might be neuroprotective (ie, that it saves neurons from damage caused by PD), though there have not yet been studies in humans that demonstrate this effect.

Cannabinoids (the drug molecules in marijuana) have also been studied for use in treating other symptoms, like bradykinesia (slowness caused by PD) and dyskinesia (excess movement caused by levodopa). Despite some promising preclinical findings, researchers have not found any meaningful or conclusive benefits of cannabis for people with PD.

The two primary components (ie, cannabinoids) of marijuana are delta-9-tetrahydrocannibinol (THC) and cannabidiol (CBD). THC and CBD act on the cannabinoid receptors type 1 (CB1) and type 2 (CB2), which are primarily found throughout the nervous system and on cells of the immune system. The way that THC and CBD acts on these two receptors is different and may help explain the different effects mediated by each of these compounds. For example, THC is the psychoactive component of marijuana and causes alterations in perception and mood. CBD, on the other hand, can reduce anxiety and may have anti-inflammatory properties.

The various compounds present in different marijuana plants and their variable effects on the CB1 and CB2 receptors make cannabis studies difficult to conduct. When researchers study the effects of a medication, dosages are controlled and often set to a specific number of milligrams. When testing medical marijuana, the dosage administered can vary dramatically depending on the plant and method of administration.

The use of cannabinoids has been suggested to help with managing neurological and non-neurological conditions. Literature on medical marijuana is incredibly varied. Studies have not clearly supported the use of marijuana for PD. The clinical studies of cannabis as a PD treatment that have been conducted are generally small studies that are predisposed to biases. Most of studies have not followed the clinical trial gold standard of a double blind, placebo-controlled trial design. Some studies had as few as five subjects.

While some results have been positive, the effects of medical marijuana are probably not completely understood. This is why more studies, especially those with more subjects, are needed.

There are risks and benefits associated with the use of cannabis for people with PD. Benefits include a possible improvement in anxiety, pain, sleep dysfunction, weight loss and nausea. Potential adverse effects include impaired cognition (specifically in executive function, or planning and judgement), dizziness, blurred vision, mood and behavioral changes, loss of balance and hallucinations. Chronic use of marijuana can increase the risk of mood disorders, particularly among young users, and lung cancer.

Researchers issue caution for people with PD who use cannabis particularly because of its effect on thinking. PD can impair the executive function the ability to make plans and limit risky behavior. People with a medical condition that impairs executive function should be cautious about using any medication that can compound this effect.

Thirty-eight states and Washington, DC have passed legislation allowing the use of marijuana-based products as a medical intervention.

In some states where medical marijuana is legalized, consumers must register to possess and use cannabis. Other states require consumers to acquire a document from a physician stating that the person has an approved condition. Under federal law doctors cannot prescribe cannabis, but many states authorize them to issue certifications that allow people to obtain medical marijuana.

PD is listed as a qualifying condition for medical marijuana in California, Connecticut, Florida, Hawaii, Illinois, Louisiana, Maine, Massachusetts, Michigan, Mississippi, Missouri, New Hampshire, New Mexico, New York, Ohio, Oklahoma, Pennsylvania, Vermont and West Virginia.

Medical marijuana is legal in Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Hawaii, Illinois, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Utah, Vermont, Virginia, Washington, West Virginia and Washington, DC.

Eighteen states and the District of Columbia have legalized the recreational use of marijuana, making it legal for adults over the age of 21 to legally consume marijuana without a doctors recommendation. Many of these states still differentiate recreational from medical marijuana. In some states, medical marijuana consumers may have access to specialized dispensaries, strains of marijuana and sales tax exemptions.

Recreational marijuana is legal in Alaska, Arizona, Connecticut, California, Colorado, Illinois, Maine, Massachusetts, Michigan, Montana, New Jersey, New Mexico, New York, Nevada, Oregon, Virginia, Vermont, Washington and Washington, DC.

Multiple states, counties or cities have decriminalized certain marijuana-related offenses. In these areas, the possession of marijuana can be met with a citation forgoing an arrest or criminal record or no penalty at all.

For state-by-state guidance on marijuana legalization, medical laws and discrimination visit Norml.org/laws.

The Parkinsons Foundation, in partnership with Northwestern University researchers, studied attitudes about cannabis at 40 Centers of Excellence members of our Global Care Network. To the best of our knowledge, this is the first study to provide data on the practices, beliefs and attitudes of expert PD physicians concerning cannabis use.

The results were interesting: most experts said they knew what cannabis did but disagreed on the details. While there is no general agreement on what the benefits might be for people with PD, the survey confirmed that cannabis is a popular subject within Parkinsons Foundation centers, as 95 percent of neurologists reported people have asked them to prescribe it.

These cannabis study results also included:

The study emphasized that physicians would be more apt to use medical marijuana as a treatment if it was approved through regulation instead of legislation. Nearly all medications are only approved after passing a science-based evaluation proving their effectiveness in a process overseen by the Food and Drug Administration. Since cannabis has been approved through legislation rather than regulation, there are no labels, dosage recommendations or timing instructions that physicians can reference.

What's next for a person with PD who wants to know if medical marijuana is an option? "Marijuana should never be thought of as a replacement for dopaminergic and other approved therapies for PD," said Dr. Michael S. Okun, the Parkinson's Foundation National Medical Advisor.

Research is still needed to determine how medical marijuana should be administered and how its long-term use can affect symptoms of PD. To keep people safe, states that legalize medical marijuana will eventually need to develop training programs for doctors and medical teams that prescribe medical marijuana. Consult your doctor to see if medical marijuana is an option for you.

The Parkinsons FoundationConsensus Statement on the Use of Medical Cannabis for Parkinsons Disease is designed to help guide the PD community in making informed decisions about using cannabis for Parkinsons. The statement is based on the input from 46 experts who attended the Foundations first-ever medical marijuana convening. Read it now.

Page reviewed by Dr. Chauncey Spears, Clinical Assistant Professor and Dr. Sydney M. Spagna, Clinical Fellow at the University of Michigan.

READ NOW

READ NOW

READ NOW

Visit link:
Medical Marijuana | Parkinson's Foundation